Edward Kiel
Corporate Officer/Principal chez Cole Schotz Meisel Forman & Leonard PA
Profil
Edward Kiel is currently a Partner at Cole Schotz Meisel Forman & Leonard PA.
Previously, he worked as a Director at SMART Biosciences, Inc. He received a graduate degree from the University of Notre Dame and an undergraduate degree from Rutgers State University of New Jersey.
Postes actifs de Edward Kiel
| Sociétés | Poste | Début |
|---|---|---|
Cole Schotz Meisel Forman & Leonard PA
 Cole Schotz Meisel Forman & Leonard PA Miscellaneous Commercial ServicesCommercial Services Cole Schotz Meisel Forman & Leonard PA is a coalition of over 170 attorneys that work together to provide legal services to businesses and select individuals. Cole Schotz Meisel Forman & Leonard PA is based in Hackensack, NJ and has subsidiaries in the United States. The private company has a nationwide reach and represent clients in various legal matters. The company was founded in 1928 and has over 120 attorneys. | Corporate Officer/Principal | 07/04/2009 |
Anciens postes connus de Edward Kiel
| Sociétés | Poste | Fin |
|---|---|---|
SMART Biosciences, Inc.
 SMART Biosciences, Inc. BiotechnologyHealth Technology At SMART Biosciences they are engaged in a coordinated effort to discover and develop novel small-molecule therapeutics to treat major age-related illnesses, including Alzheimer's disease and various forms of cancer. Since its beginning in 2005, as a spin-off of Columbia University, they have been working to address significant unmet therapeutic needs in these large and rapidly growing markets. Through its affiliation with Columbia University, SMART holds exclusive worldwide licenses to valuable intellectual property. Its scientists have identified several novel targets in two therapeutic areas that have the potential for new treatments in: Alzheimer's disease--a novel lipid target that modulates levels of neurotoxic beta-amyloid in the brain, Cancer--novel targets that modulate p53 stability, increasing tumor-cell sensitivity to cytotoxic and radiation therapies. They believe its intellectual property and scientific rationale for future compound discovery offers a compelling opportunity for commercialization. SMART is led by management and scientific advisory teams comprised of preeminent professionals distinguished in the worlds of academic science, pharmaceutical discovery, business/corporate development, finance and intellectual property law. The SMART Biosciences leadership team brings scientific rigor, business leadership, and innovation experience to its endeavors. Its discovery and development strategy employs a unique-to-the-industry collaborative network of advanced business, academic and R&D interests throughout the United States and Asia. | Directeur/Membre du Conseil | 13/02/2012 |
Formation de Edward Kiel
| Rutgers State University of New Jersey | Undergraduate Degree |
| University of Notre Dame | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
SMART Biosciences, Inc.
SMART Biosciences, Inc. BiotechnologyHealth Technology At SMART Biosciences they are engaged in a coordinated effort to discover and develop novel small-molecule therapeutics to treat major age-related illnesses, including Alzheimer's disease and various forms of cancer. Since its beginning in 2005, as a spin-off of Columbia University, they have been working to address significant unmet therapeutic needs in these large and rapidly growing markets. Through its affiliation with Columbia University, SMART holds exclusive worldwide licenses to valuable intellectual property. Its scientists have identified several novel targets in two therapeutic areas that have the potential for new treatments in: Alzheimer's disease--a novel lipid target that modulates levels of neurotoxic beta-amyloid in the brain, Cancer--novel targets that modulate p53 stability, increasing tumor-cell sensitivity to cytotoxic and radiation therapies. They believe its intellectual property and scientific rationale for future compound discovery offers a compelling opportunity for commercialization. SMART is led by management and scientific advisory teams comprised of preeminent professionals distinguished in the worlds of academic science, pharmaceutical discovery, business/corporate development, finance and intellectual property law. The SMART Biosciences leadership team brings scientific rigor, business leadership, and innovation experience to its endeavors. Its discovery and development strategy employs a unique-to-the-industry collaborative network of advanced business, academic and R&D interests throughout the United States and Asia. | Health Technology |
Cole Schotz Meisel Forman & Leonard PA
Cole Schotz Meisel Forman & Leonard PA Miscellaneous Commercial ServicesCommercial Services Cole Schotz Meisel Forman & Leonard PA is a coalition of over 170 attorneys that work together to provide legal services to businesses and select individuals. Cole Schotz Meisel Forman & Leonard PA is based in Hackensack, NJ and has subsidiaries in the United States. The private company has a nationwide reach and represent clients in various legal matters. The company was founded in 1928 and has over 120 attorneys. | Commercial Services |
